Monoclonal antibodies that target CD20 expressing B cells represent an important new
treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly …

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative
disease affecting the central nervous system (CNS), often characterized by the accumulation …

B cells play a vital function in multiple sclerosis (MS) pathogenesis through an array of
effector functions. All currently approved MS disease–modifying therapies alter the …

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that is caused by an
autoimmune response against central nervous system (CNS) structures. Traditionally …

Recent years have substantially broadened our view on the pathogenesis of multiple
sclerosis (MS). While earlier concepts focused predominantly on T lymphocytes as the key …

Several clinical trials have demonstrated the efficacy of lytic therapies targeting B cells in the
treatment of relapsing multiple sclerosis (MS). More modest efficacy has been noted in the …

Multiple sclerosis (MS) was previously thought to be a T-cell-mediated, demyelinating
disease of the central nervous system. Disease-modifying therapies targeting T cells have …

B cells, plasma cells and antibodies may play a key role in the pathogenesis of multiple
sclerosis (MS). This notion is supported by various immunological changes observed in MS …

The recently successful targeting of B cells in patients with multiple sclerosis (MS) using
monoclonal antibodies (mAbs) targeting CD20 has established that it is no longer a question …

The immune system plays a significant role in multiple sclerosis. While MS was historically
thought to be T cell-mediated, multiple pieces of evidence now support the view that B cells …